Log in
Enquire now
Imvax

Imvax

Imvax is a clinical-stage biotechnology company focused on the development of patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers with unmet medical needs.

OverviewStructured DataIssuesContributors
Is a
Company
Company
Organization
Organization
CEO
‌
John Furey
0
CFO
‌
Josh Muntner
0
Company Operating Status
Active
COO
‌
Sean P. Hemingway
0
Country
United States
United States
0
Crunchbase URL
crunchbase.com/organiz...on/imvax
Date Incorporated
2015
Email Address
contact@imvax.com
Founded Date
2015
Founder
‌
D. Craig Hooper
‌
Peter Corr
‌
Arthur W. Howe
‌
David Andrews (entrepreneur)
0
Full Address
601 Walnut Street, Suite 440W, Philadelphia, PA 19106
Industry
Therapeutics
Therapeutics
Biomedical engineering
Biomedical engineering
Biopharmaceutical
Biopharmaceutical
Technology
Technology
Biotechnology
Biotechnology
Biology
Biology
Healthcare
Healthcare
Regenerative medicine
Regenerative medicine
Cell therapy
Cell therapy
Stem cell
Stem cell
•••
Latest Funding Round Date
July 2020
Latest Funding Round Amount (USD)
112,370,500
Latest Funding Type
Series B
Series B
LinkedIn URL
@company/imvax-inc
Location
Philadelphia
Philadelphia
0
Phone Number
+12154850071
+12679004110
Pitchbook URL
pitchbook.com/profiles...267714-64
Total Funding Amount (USD)
192,370,500
Twitter URL
@imvax_inc
Official Website
imvax.com

Find more companies like Imvax

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.